The Homocysteine Hypothesis of Depression
Abstract
High levels of homocysteine are associated with cerebrovascular disease, monoamine neurotransmitters, and depression of mood. A plausible hypothesis for these associations is that high homocysteine levels cause cerebral vascular disease and neurotransmitter deficiency, which cause depression of mood. The homocysteine depression hypothesis, if true, would mandate inclusions of imaging studies for cerebrovascular disease and measures of homocysteine, folate, and B 12 and B 6 vitamins in the clinical evaluation of older depressed patients. Longitudinal studies and clinical trials should be designed to challenge the hypothesis.
If depression of mood is in some cases a symptom of disease, knowledge of etiology would lead to prevention and knowledge of pathogenesis would lead to a cure. Although there probably are multiple genetic and environmental causes of depression, we review the evidence here to support one hypothesis or model of depression as a disease. The hypothesis is that genetic and environmental factors elevate homocysteine levels, which cause vascular disease of the brain, and/or transmitter alterations, which cause depression.
Background
We provide background information, recently reviewed by Coppen and Bolander-Gouaille (1) , and then review studies supporting the hypothesis. Homocysteine is a sulfurated amino acid derived from ingested methionine found in cheeses, eggs, fish, meat, and poultry. It is directly toxic to neurons and blood vessels and can induce DNA strand breakage, oxidative stress, and apoptosis (2 , 3) . The methionine-homocysteine metabolic pathway intermediaries are S -adenosylmethionine and S -adenosylhomocysteine. The pathway produces methyl groups required for the synthesis of catecholamines and DNA. This is accomplished by remethylating homocysteine—using B 12 and folate as cofactors—back to methionine. Homocysteine is cleared by transulfuration to cysteine and glutathione, an important antioxidant. Transulfuration requires vitamins B 6 and B 12 .
The components of the homocysteine-methionine cycle, as well as cysteine and glutathione and the enzymes of the pathway, are affected by genetic variation, diet, kidney and gastrointestinal diseases, and prescribed and over-the-counter drugs. Since homocysteine is a sensitive indicator of B vitamin deficiency, an elevated homocysteine level is a marker for a pathogenic process as well as a cause of pathology.
Evidence Supporting the Hypothesis
Prevalence of Hyperhomocysteinemia in the Population and in Disease
Homocysteine levels are higher in the elderly and in men (4) . In 1,160 adults from the original Framingham Heart Study cohort who had survived to 67 to 96 years of age, a high homocysteine level (>14 mmol/liter) was present in 29.3%. Homocysteine levels were correlated with age and correlated inversely with folate and vitamins B 6 and B 12(5) . In another study, of women ages 15 to 44, 13% of the sample had elevated total plasma homocysteine levels, defined as a concentration ≥10.0 mmol/liter (6) .
Samples of geriatric patients have higher levels of homocysteine than do samples of community-dwelling elderly. For example, among patients ages 65 and over who were admitted into an acute care geriatric ward in Northern Italy, 74.2% of men and 68.9% of women had elevated homocysteine levels. Elevated total plasma homosysteine concentrations were associated with older age, male gender, increasing serum creatinine, lower Mini-Mental State Examination score, and disability (4) .
Some studies find elevated levels of homocysteine in Alzheimer’s disease (7 , 8) and cognitive impairment (9) , but others do not (10 , 11) . Hyperhomocysteinemia was also present in 20% of stroke patients but only 2.2% of comparison subjects (odds ratio=5.75; 95% confidence interval [CI]=1.24–53.4, p<0.01) (12) .
Causes of Hyperhomocysteinemia
Serum levels of homocysteine increase after methionine loading; in dietary deficiency of B 12 , folate, and B 6(13) ; and because of renal disease (14 , 15) and genetic variation of the enzymes (such as methyl-tetrahydro-folate reductase [ MTHFR ] and cystathionine beta-synthatase [ CBS ]) essential for the metabolism of homocysteine. Other causes of hyperhomocysteinemia include gastric atrophy (16) , inflammatory bowel disease (17) , and laxative use (18) , all of which interfere with absorption of nutrients. Anticonvulsants and diuretics elevate homocysteine levels (19) .
Homocysteine and Vascular Disease
The association between homocysteine and vascular disease has been documented in studies of genetic variation and from population-based studies of prevalence and incidence. McCully (20) first described the similarity of the homocystinuric vascular lesions to atherosclerosis in two autopsied cases of children with homocystinuria. Furthermore, he showed that the lesions of atherosclerosis could be induced in rabbits by administering either dietary or parenteral methionine or homocysteic acid parenterally. The rabbits died from pulmonary embolism and pulmonary infarct (21) .
Genetic Mutations Elevate Homocysteine Levels
Mutations of MTHFR and CBS genes cause a rare recessive genetic disease: homocystinuria. It was first described in 1962 when Carson and Neil, screening urine for amino acid abnormalities in mentally retarded subjects, found four cases of elevated homocysteine levels of 2,000 screened. It was clear from later studies that vascular disease was a regular feature of the phenotype (22) . In patients with homocystinuria, the probability of having a clinically detected thromboembolic event by age 15 was 27%, and the probability of not surviving to age 30 was 23% (23) . Many mutations have been discovered to cause homocystinuria. Another feature of homocystinuria is the high prevalence of psychiatric disorders. In a study of 63 homocystinuric patients who had been treated with B 6 , the overall rate of clinically significant psychiatric disorders was 51%, including episodic depression (10%), chronic disorders of behavior (17%), chronic obsessive-compulsive disorder (5%), and personality disorders (19%). The average IQ was 80 (SD=27) (24) . In summary, mutations of genes regulating homocysteine metabolism cause mental retardation, vascular brain disease, and psychiatric symptoms.
In addition to the mutations that cause homocystinuria, there are several known allelic variants of the MTHFR gene. Approximately 10% of the population carries the c67TT MTHFR allele, which is associated with elevated homocysteine levels (25) . These normal variants increase the risk for myocardial infarction and ischemic stroke, particularly among younger patients and women (26 – 32) . However, two studies showed no association between the c67TT allele and stroke (25 , 33) .
Interaction of genes and environment were found in a study from Hungary that demonstrated that MTHFR c67TT alleles, when combined with environmental effects, such as drinking or smoking, increased the risk of vascular disease more than the alleles or environmental factors by themselves (34) . Many other genes in the methionine pathway are known, but their allelic variants have not yet been explored for clinical associations.
Elevated Homocysteine Levels and Risk
Maternal deficiency of folate and elevated homocysteine levels during pregnancy increase the risk of neural tube defects and possibly schizophrenia (35 – 37) . By 1989, elevated homocysteine was established as an independent risk for vascular disease. Ueland and Refsum (38) , distinguished investigators in this area, noted, “Impaired homocysteine metabolism seems to exist in 15–30% of patients with premature cardiovascular disease. Moderate hyperhomocysteinemia is a risk factor for cardiovascular disease, independent of conventional risk factors.”
Results of a recent meta-analysis of prospective studies suggest that lowering the serum homocysteine level by 25% (about 3 mmol/liter) decreases the risk for ischemic heart disease. Reduction of levels reduces the risk of heart disease by 11% and stroke by 19% (16) . Another meta-analysis of 72 studies concluded that “lowering homocysteine concentrations by 3 micromol/liter from current levels (achievable by increasing folic acid intake) would reduce the risk of ischemic heart disease by 16%, deep vein thrombosis by 25%, and stroke by 24%” (39) .
A dose-response relationship was found in a prospective study in Rotterdam. The risk of stroke and myocardial infarction increased directly with total homocysteine level (6% to 7% for every 1 mmol/liter increase in total homocysteine level) (40 , 41) . Studies in other countries report the same dose-response relationship between homocysteine and vascular disease (42 , 43) . Such cross-national studies are important because of regional variations in diet and gene frequencies. In addition to clinically diagnosed stroke, silent brain infarcts, diagnosed by magnetic resonance imaging (MRI), and ischemic white matter disease are also associated with elevated levels of homocysteine (44 – 46) .
Further support for the idea that homocysteine is a cause of vascular disease comes from studies indicating that increasing intake of dietary folate, which effectively lowers homocysteine levels, lowers the risk of ischemic stroke in men (47 , 48) .
In summary, elevated levels of homocysteine, and in some populations, alleles of the MTHFR genotype, increase the risk for vascular disease of the brain. The proportion of all strokes due to this mechanism is not known but likely varies by age, geographic location, and prevalence of known causes of elevated homocysteine levels.
Intervention Studies
Results of recent intervention studies designed to lower homocysteine levels are mixed. Although homocysteine levels can be reduced, vascular disease is not prevented (49 – 53) . Explanations for this failure include lack of adequate power and selection criteria, which include cases in which documented vascular disease has already occurred.
Nevertheless, cognitive improvement has been found after homocysteine levels were lowered (54 , 55) . Depression has been relieved by lowering homocysteine levels with B vitamin supplementation (56) .
Stroke As a Cause of Depression
If homocysteine causes vascular disease, is vascular disease then the intermediate cause of hyperhomocysteinemia-related depression? Depression as a specific feature of stroke was first described in a small case-control study using a detailed structured clinical psychiatric interview of patients in a rehabilitation program following stroke and orthopedic conditions. Depression was more often found in stroke patients than in orthopedic patients matched for levels of disability (57) . Because the groups were matched for disability, the increased rate of depression in stroke patients could not be attributed only to a psychological reaction to loss of function, i.e., disability. Since then, Robinson (58) and many others have extensively studied poststroke depression. In a review, Robinson noted that “Pooled data from studies conducted throughout the world have found prevalence rates for major depression of 19.3% among hospitalized stroke patients and 23.3% among outpatient samples.” There is evidence that antidepressants improve mood after stroke but no evidence that depression can be prevented (58 , 59) .
Further evidence of the specificity of depression caused by stroke comes from studies indicating that left hemisphere stroke commonly causes depression. Narushima et al. (60) showed in a meta-analysis that there was a significant inverse correlation between severity of depression and distance of the lesion from the frontal pole among 163 patients with left hemisphere stroke but not among 106 patients with right hemisphere stroke.
Cardiovascular Disease and Depression
Stroke is often associated with heart disease, and depression is a symptom and a risk for heart disease (61) . The pathogenesis of depression in heart disease is not known. Possible mechanisms include cerebral infarcts and drugs used to treat depression and heart disease, including diuretics and anticonvulsants (62) .
Vascular Disease in Depressed Populations
Several studies indicate that a large proportion of elderly persons with depression also have had either a stroke or other evidence of vascular disease. Many studies find high rates of cerebrovascular disease and white matter lesions on MRI in depressed elderly patients. For example, in a Japanese study in which patients were matched for age, the frequency of silent cerebral infarction varied with both age and the age of depression onset. Among patients over the age of 65 diagnosed with major depression, silent cerebral infarction was observed in 65.9% of those with depression onset before the age of 65 and in 93.7% of those with onset of depression after age 65 (63) . In other studies, deep white matter lesions were most common in patients who first presented with depression late in life (64 – 67) . Coffey et al. (68) identified changes in subcortical white matter lesions in 44 of 67 depressed inpatients (66%) referred for ECT. Two autopsy studies demonstrated that the white matter intensities seen in the MRIs of patients with depression were ischemic lesions (69 , 70) .
Alexopoulos et al. (71) observed a characteristic cognitive pattern in depressed patients with vascular disease. In 1997, he named these cases “vascular depression.” Vascular disease was found in 75 of 139 depressed patients (54%). The vascular group was older and had more hypertension and less family history of depression (72) . Furthermore, a severe reduction in mental speed remained after recovery from the depressive episode, which suggested underlying brain disease, such as infarcts (73) . Recently, the concept of vascular depression has been challenged (74 – 76) .
Although elderly depressive patients are often the subjects of studies of vascular disease and depression, one study found scan abnormalities associated in children with psychiatric disorders. White matter hyperintensities of 153 child and adolescent psychiatry inpatients were rated on T 2 -weighted MRI scans. Within the unipolar depression group (N=48), white matter hyperintensities were significantly associated with a higher prevalence of past suicide attempts (p=0.03, Fisher’s exact test) (77) . However, in another study, increased rates of white matter hyperintensities were not found in young patients with mood disorders (78) .
Several studies have shown that premorbid depression can significantly increase the risk of stroke over the subsequent 10–15 years. Depression has been reported to be a risk for vascular disease in several large population-based prospective studies (e.g., reference 79 ). However, these studies did not include baseline MRI scans to document the absence of preexisting cerebrovascular disease. In summary, depression occurs frequently after stroke, and high proportions of imaging studies of older depressed patients show infarcts or white matter lesions that indicate the presence of ischemic vascular disease.
Homocysteine and Neurotransmitter Alterations
Homocysteine and stroke might cause depression by alteration of neurotransmitters (80 , 81) . Evidence for the association between homocysteine and neurotransmitters is found in studies that directly measure neurotransmitter metabolites and in studies demonstrating the antidepressant effects of folate and S -adenosylmethionine, a cofactor and an intermediate metabolite of the methionine-homocysteine pathway.
The most direct evidence for the association between homocysteine and neurotransmitters is from a study showing that depressed patients with increased total plasma homocysteine levels had significantly lower levels of serum, red cells, and CSF folate, as well as lower levels of CSF S -adenosylmethionine (SAMe). The depressed patients with high total plasma homocysteine levels were also found to have significantly lower mean CSF concentrations of 5-hydroxyindoleacetic acid, homovanillic acid, and 3-methoxy-4-hydroxyphenylglycol (MHPG) (82) .
The relationship between homocysteine and neurotransmitters is indirectly suggested by studies showing that mood can be modified by alteration of the homocysteine pathway. S -adenosylmethionine, an intermediary in the homocysteine pathway, has been found to function as an antidepressant. Its effects have been shown to be superior to placebo and comparable to standard tricyclic antidepressants (83 , 84) . In addition, three randomized trials have suggested supplemental folate as a treatment for depression (85 , 86) . In a study of depressed patients who had failed to benefit from paroxetine treatment but were currently receiving other treatments, low serum folate levels were found to be associated with poorer response to those treatments (87) . Relapse of depression has also been found to be related to folate (88 , 89) . The improvement in mood following S -adenosylmethionine or supplemental folate administration suggests the involvement of the homocysteine pathway in depression (90) .
Direct evidence of the association between homocysteine and neurotransmitter levels comes from studies of Parkinson’s disease. Parkinson’s patients receiving L -dopa, which requires the donation of a methyl group from S -adenosylmethionine to be metabolized, had higher levels of homocysteine than patients not taking L -dopa (91) . Use of L -dopa could create a methyl sink, thus preventing the remethylation of homocysteine to methionine with the result of high homocysteine levels. Another potential mechanism for the homocysteine effect on transmitters is by inhibition of the enzyme necessary to catalyze the methylation reactions between the catecholamines and S -adenosylmethionine (SAMe) (92 – 94) .
Association of Homocysteine and Depressive Disorders
The relationship of the homocysteine-methyl donor pathway to depression was noted first by Reynolds and colleagues (95 – 98) in the 1970s. Subsequent clinical and population-based studies have noted elevated homocysteine levels in depression (82 , 99) . Associations between homocysteine, folate, B 12 , and depression vary in particular populations. The Hordaland study of older men and women in Norway found that elevated homocysteine coupled with the T/T allele of MTHFR gene was associated with depression but that folate and B 12 without the T/T allele were not associated (100 , 101) . The Rotterdam study of older men and women found that hyperhomocysteinemia, vitamin B 12 deficiency, and—to a lesser extent—folate deficiency were related to depressive disorders (102) .
Two studies of special populations did not find that homocysteine was related to depression. The first included women only and found vitamin B 12 deficiency to be present in 14.9% of the 478 nondepressed subjects, 17.0% of the 100 mildly depressed subjects, and 27.0% of the 122 severely depressed subjects. No association was found between homocysteine and depression or folate and depression (103) . The second was an ethnically diverse U.S. population sample ages 15–39 years. Subjects with any lifetime diagnosis of major depression had serum and red blood cell folate concentrations that were lower than those of subjects who had no history of depression. In this young population, serum homocysteine was not found to be associated with lifetime depression diagnoses (104) . Homocysteine, B 12 , folate, or some combination is related to depression, but age, sex, race, and renal function must be specified. Because there are many types of depression in populations of different ages, as well as many causes for elevated homocysteine, including genetic predisposition and brain disease, samples of randomly selected subjects will be heterogeneous. Therefore, adequate power to demonstrate a specific relationship necessitates large samples.
Conclusions
There is strong published evidence for the association between homocysteine level and depression, vascular disease, and neurotransmitters. More large population-based prospective studies are needed to challenge the idea that elevated homocysteine levels cause vascular disease, which causes depression. Intervention trials are needed to determine whether depression treatment will be enhanced by homocysteine reduction. Since there are many causes of elevated homocysteine levels and probably many causes of depression, prospective and intervention studies must include a large enough sample to ensure adequate power to demonstrate outcome. Subjects included in prevention studies should not have depression, vascular disease, or elevated homocysteine levels at baseline.
If the hypothesis is not rejected by further study, then evaluation of elderly depressed patients should include imaging for vascular disease and measurement of homocysteine, folate, B 6 , and B 12 levels.
1. Coppen A, Bolander-Gouaille C: Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol 2005; 19:59–65Google Scholar
2. Mattson MP, Shea TB: Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003; 26:137–146Google Scholar
3. Lipton SA, Kim WK, Choi YB, Kumar S, D’Emilia DM, Rayudu PV, Arnelle DR, Stamler JS: Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 1997; 94:5923–5928Google Scholar
4. Marengoni A, Cossi S, De Martinis M, Calabrese PA, Orini S, Grassi V: Homocysteine and disability in hospitalized geriatric patients. Metabolism 2004; 53:1016–1020Google Scholar
5. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693–2698Google Scholar
6. Giles WH, Kittner SJ, Croft JB, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Price TR, McCarter RJ, Macko RF, Johnson CJ, Feeser BR, Earley CJ, Buchholz DW, Stolley PD: Distribution and correlates of elevated total homocyst(e)ine: the Stroke Prevention in Young Women Study. Ann Epidemiol 1999; 9:307–313Google Scholar
7. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM: Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55:1449–1455Google Scholar
8. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, Wilson PW, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002; 346:476–483Google Scholar
9. Wright CB, Lee HS, Paik MC, Stabler SP, Allen RH, Sacco RL: Total homocysteine and cognition in a tri-ethnic cohort: the Northern Manhattan Study. Neurology 2004; 63:254–260Google Scholar
10. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R: Plasma homocysteine levels and risk of Alzheimer disease. Neurology 2004; 62:1972–1976Google Scholar
11. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM: Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 1999; 150:283–289Google Scholar
12. Yoo JH, Chung CS, Kang SS: Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998; 29:2478–2483Google Scholar
13. Selhub J, Jacques PF, Bostom AG, Wilson PW, Rosenberg IH: Relationship between plasma homocysteine and vitamin status in the Framingham study population: impact of folic acid fortification. Public Health Rev 2000; 28:117–145Google Scholar
14. Clarke R, Lewington, S, Landray M: Homocysteine, renal function, and risk of cardiovascular disease. Kidney Int Suppl 2003; 84:S131–S133Google Scholar
15. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH: The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12:2181–2189Google Scholar
16. Wolters M, Strohle A, Hahn A: [Age-associated changes in the metabolism of vitamin B(12) and folic acid: prevalence, aetiopathogenesis and pathophysiological consequences] (German). Z Gerontol Geriatr 2004; 37:109–135Google Scholar
17. Romagnuolo J, Fedorak RN, Dias VC, Bamforth F, Teltscher M: Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am J Gastroenterol 2001; 96:2143–2149Google Scholar
18. Nilsson SE, Takkinen S, Johansson B, Dotevall G, Melander A, Berg S, McClearn G: Laxative treatment elevates plasma homocysteine: a study on a population-based Swedish sample of old people. Eur J Clin Pharmacol 2004; 60:45–49Google Scholar
19. Westphal S, Rading A, Luley C, Dierkes J: Antihypertensive treatment and homocysteine concentrations. Metabolism 2003; 52:261–263Google Scholar
20. McCully KS: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111–128Google Scholar
21. McCully KS, Wilson RB: Homocysteine theory of arteriosclerosis. Atherosclerosis 1975; 22:215–227Google Scholar
22. Schimke RN, McKusick VA, Huang T, Pollack AD: Homocystinuria: studies of 20 families with 38 affected members. JAMA 1965; 193:711–719Google Scholar
23. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R, et al: The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37:1–31Google Scholar
24. Abbott MH, Folstein SE, Abbey H, Pyeritz RE: Psychiatric manifestations of homocystinuria due to cystathionine beta-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and vitamin B6-responsiveness. Am J Med Genet 1987; 26:959–969Google Scholar
25. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J: A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997; 28:1739–1743Google Scholar
26. Kim RJ, Becker RC: Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146:948–957Google Scholar
27. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL: Homocysteine, MTHFR 677C–>T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002; 59:529–536Google Scholar
28. Kohara K, Fujisawa M, Ando F, Tabara Y, Niino N, Miki T, Shimokata H, NILS-LSA Study: MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: the NILS-LSA Study. Stroke 2003; 34:1130–1135Google Scholar
29. Gillum RF: Distribution of total serum homocysteine and its association with parental history and cardiovascular risk factors at ages 12–16 years: the Third National Health and Nutrition Examination Survey. Ann Epidemiol 2004; 14:229–233Google Scholar
30. Prengler M, Sturt N, Krywawych S, Surtees R, Liesner R, Kirkham F: Homozygous thermolabile variant of the methylenetetrahydrofolate reductase gene: a potential risk factor for hyperhomocysteinaemia, CVD, and stroke in childhood. Dev Med Child Neurol 2001; 43:220–225Google Scholar
31. Li Z, Sun L, Zhang H, Liao Y, Wang D, Zhao B, Zhu Z, Zhao J, Ma A, Han Y, Wang Y, Shi Y, Ye J, Hui R, Multicenter Case-Control Study in China: Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China. Stroke 2003; 34:2085–2090Google Scholar
32. Choi BO, Kim NK, Kim SH, Kang MS, Lee S, Ahn JY, Kim OJ, Kim S, Oh D: Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions. Thromb Res 2003; 111:39–44Google Scholar
33. Ucar F, Sonmez M, Ovali E, Ozmenoglu M, Karti SS, Yilmaz M, Pakdemir A: MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population. Am J Hematol 2004; 76:40–43Google Scholar
34. Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Fodor L, Bene J, Melegh B: Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke. J Neurol Neurosurg Psychiatry 2003; 74:1615–1620Google Scholar
35. Zhao W, Mosley BS, Cleves MA, Melnyk S, James J, Hobbs CA: Neural tube defects and maternal biomarkers of folate, homocysteine, and glutathione metabolism. Birth Defects Res A Clin Mol Teratol 2006; 76:230–236Google Scholar
36. Eichholzer M, Tonz O, Zimmermann R: Folic acid: a public-health challenge. Lancet 2006; 367:1352–1361Google Scholar
37. Brown AS, Bottiglieri T, Schaefer CA, Quesenberry CP Jr, Liu L, Bresnahan M, Susser ES: Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry 2007; 64:31–39Google Scholar
38. Ueland PM, Refsum H: [Plasma homocysteine, a risk factor for premature vascular disease: plasma levels in healthy persons; during pathologic conditions and drug therapy] (Norwegian). Nord Med 1989; 104:293–298Google Scholar
39. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202Google Scholar
40. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, Koudstaal PJ, Grobbee DE: Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999; 159:38–44Google Scholar
41. Kittner SJ, Giles WH, Macko RF, Hebel JR, Wozniak MA, Wityk RJ, Stolley PD, Stern BJ, Sloan MA, Sherwin R, Price TR, McCarter RJ, Johnson CJ, Earley CJ, Buchholz DW, Malinow MR: Homocyst(e)ine and risk of cerebral infarction in a biracial population: the stroke prevention in young women study. Stroke 1999; 30:1554–1560Google Scholar
42. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI: Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000; 31:1069–1075Google Scholar
43. Sasaki T, Watanabe M, Nagai Y, Hoshi T, Takasawa M, Nukata M, Taguchi A, Kitagawa K, Kinoshita N, Matsumoto M: Association of plasma homocysteine concentration with atherosclerotic carotid plaques and lacunar infarction. Stroke 2002; 33:1493–1496Google Scholar
44. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, Breteler MM: Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 2002; 51:285–289Google Scholar
45. Longstreth WT Jr, Katz R, Olson J, Bernick C, Carr JJ, Malinow MR, Hess DL, Cushman M, Schwartz SM: Plasma total homocysteine levels and cranial magnetic resonance imaging findings in elderly persons: the Cardiovascular Health Study. Arch Neurol 2004; 61:67–72Google Scholar
46. Matsui T, Arai H, Yuzuriha T, Yao H, Miura M, Hashimoto S, Higuchi S, Matsushita S, Morikawa M, Kato A, Sasaki H: Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke 2001; 32:1116–1119Google Scholar
47. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A: Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 2004; 35:169–174Google Scholar
48. Al-Delaimy WK, Rexrode KM, Hu FB, Albert CM, Stampfer MJ, Willett WC, Manson JE: Folate intake and risk of stroke among women. Stroke 2004; 35:1259–1263Google Scholar
49. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr, Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354:1567–1577Google Scholar
50. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291:565–575Google Scholar
51. Durga J, van Tits LJ, Schouten EG, Kok FJ, Verhoef P: Effect of lowering of homocysteine levels on inflammatory markers: a randomized controlled trial. Arch Intern Med 2005; 165:1388–1394Google Scholar
52. Herrmann W: Significance of hyperhomocysteinemia. Clin Lab 2006; 52:367–374Google Scholar
53. Malouf M, Grimley EJ, Areosa SA: Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev 2003; CD004514Google Scholar
54. Wouters-Wesseling W, Wagenaar LW, Rozendaal M, Deijen JB, de Groot LC, Bindels JG, van Staveren WA: Effect of an enriched drink on cognitive function in frail elderly persons. J Gerontol A Biol Sci Med Sci 2005; 60:265–270Google Scholar
55. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P: Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 2007; 369:208–216Google Scholar
56. Coppen A, Bailey J: Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000; 60:121–130Google Scholar
57. Folstein MF, Maiberger R, McHugh PR: Mood disorder as a specific complication of stroke. J Neurol Neurosurg Psychiatry 1977; 40:1018–1020Google Scholar
58. Robinson RG: Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003; 54:376–387Google Scholar
59. Hackett ML, Anderson CS, House AO: Interventions for treating depression after stroke. Cochrane Database Syst Rev 2004; CD003437Google Scholar
60. Narushima K, Kosier JT, Robinson RG: A reappraisal of poststroke depression, intra- and interhemispheric lesion location using meta-analysis. J Neuropsychiatry Clin Neurosci 2003; 15:422–430Google Scholar
61. Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A: Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int J Geriatr Psychiatry 2007; Jan 19 (Epub ahead of print)Google Scholar
62. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G: Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. Metabolism 2001; 50:1466–1471Google Scholar
63. Fujikawa T, Yamawaki S, Touhouda Y: Incidence of silent cerebral infarction in patients with major depression. Stroke 1993; 24:1631–1634Google Scholar
64. O’Brien J, Desmond P, Ames D, Schweitzer I, Harrigan S, Tress B: A magnetic resonance imaging study of white matter lesions in depression and Alzheimer’s disease. Br J Psychiatry 1996; 168:477–485Google Scholar
65. Tupler LA, Krishnan KR, McDonald WM, Dombeck CB, D’Souza S, Steffens DC: Anatomic location and laterality of MRI signal hyperintensities in late-life depression. J Psychosom Res 2002; 53:665–676Google Scholar
66. Artero S, Tiemeier H, Prins ND, Sabatier R, Breteler MM, Ritchie K: Neuroanatomical localisation and clinical correlates of white matter lesions in the elderly. J Neurol Neurosurg Psychiatry 2004; 75:1304–1308Google Scholar
67. Agid R, Levin T, Gomori JM, Lerer B, Bonne O: T2-weighted image hyperintensities in major depression: focus on the basal ganglia. Int J Neuropsychopharmacol 2003; 6:215–224Google Scholar
68. Coffey CE, Figiel GS, Djang WT, Cress M, Saunders WB, Weiner RD: Leukoencephalopathy in elderly depressed patients referred for ECT. Biol Psychiatry 1988; 24:143–161Google Scholar
69. Thomas AJ, O’Brien JT, Davis S, Ballard C, Barber R, Kalaria RN, Perry RH: Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study. Arch Gen Psychiatry 2002; 59:785–792Google Scholar
70. Thomas AJ, Perry R, Kalaria RN, Oakley A, McMeekin W, O’Brien JT: Neuropathological evidence for ischemia in the white matter of the dorsolateral prefrontal cortex in late-life depression. Int J Geriatr Psychiatry 2003; 18:7–13Google Scholar
71. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M: Clinically defined vascular depression. Am J Psychiatry 1997; 154:562–565Google Scholar
72. Krishnan KR, Taylor WD, McQuoid DR, MacFall JR, Payne ME, Provenzale JM, Steffens DC: Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psychiatry 2004; 55:390–397Google Scholar
73. Yamashita H, Fujikawa T, Yanai I, Morinobu S, Yamawaki S: Cognitive dysfunction in recovered depressive patients with silent cerebral infarction. Neuropsychobiology 2002; 45:12–18Google Scholar
74. Aben I, Lodder J, Honig A, Lousberg R, Boreas A, Verhey F: Focal or generalized vascular brain damage and vulnerability to depression after stroke: a 1-year prospective follow-up study. Int Psychogeriatr 2006; 18:19–35Google Scholar
75. Rainer MK, Mucke HA, Zehetmayer S, Krampla W, Kuselbauer T, Weissgram S, Jungwirth S, Tragl KH, Fischer P: Data from the VITA Study do not support the concept of vascular depression. Am J Geriatr Psychiatry 2006; 14:531–537Google Scholar
76. Lind K, Jonsson M, Karlsson I, Sjogren M, Wallin A, Edman A: Depressive symptoms and white matter changes in patients with dementia. Int J Geriatr Psychiatry 2006; 21:119–125Google Scholar
77. Ehrlich S, Noam GG, Lyoo IK, Kwon BJ, Clark MA, Renshaw PF: White matter hyperintensities and their associations with suicidality in psychiatrically hospitalized children and adolescents. J Am Acad Child Adolesc Psychiatry 2004; 43:770–776Google Scholar
78. Sassi RB, Brambilla P, Nicoletti M, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC: White matter hyperintensities in bipolar and unipolar patients with relatively mild-to-moderate illness severity. J Affect Disord 2003; 77:237–245Google Scholar
79. Larson SL, Owens PL, Ford D, Eaton W: Depressive disorder, dysthymia, and risk of stroke: thirteen-year follow-up from the Baltimore epidemiologic catchment area study. Stroke 2001; 32:1979–1983Google Scholar
80. Tang HZ: [The changes of monoamine metabolites in CSF of patients with cerebral stroke]. Zhonghua Shen Jing Jing Shen Ke Za Zhi 1991; 24:130–132, 186 (Chinese)Google Scholar
81. Bryer JB, Starkstein SE, Votypka V, Parikh RM, Price TR, Robinson RG: Reduction of CSF monoamine metabolites in poststroke depression: a preliminary report. J Neuropsychiatry Clin Neurosci 1992; 4:440–442Google Scholar
82. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH: Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000; 69:228–232Google Scholar
83. Bressa GM: S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994; 154:7–14Google Scholar
84. Bottiglieri T, Hyland K: S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol Scand Suppl 1994; 154:19–26Google Scholar
85. Bell KM, Plon L, Bunney WE Jr, Potkin SG: S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry 1988; 145:1110–1114Google Scholar
86. Taylor MJ, Carney SM, Goodwin GM, Geddes JR: Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol 2004; 18:251–256Google Scholar
87. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T: Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry 1997; 154:426–428Google Scholar
88. Papakostas GI, Petersen T, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M: Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry 2004; 65:1090–1095Google Scholar
89. Papakostas GI, Petersen T, Mischoulon D, Green CH, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M: Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry 2004; 65:1096–1098Google Scholar
90. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH: Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990; 336:392–395Google Scholar
91. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA: Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003; 60:1125–1129Google Scholar
92. Zhu BT: Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 2002; 3:321–349Google Scholar
93. Rivett AJ, Roth JA: Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol O-methyltransferase. Biochemistry 1982; 21:1740–1742Google Scholar
94. Kennedy BP, Bottiglieri T, Arning E, Ziegler MG, Hansen LA, Masliah E: Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J Neural Transm 2004; 111:547–567Google Scholar
95. Reynolds EH, Preece JM, Bailey J, Coppen A: Folate deficiency in depressive illness. Br J Psychiatry 1970; 117:287–292Google Scholar
96. Reynolds EH, Stramentinoli G: Folic acid, S-adenosylmethionine and affective disorder. Psychol Med 1983; 13:705–710Google Scholar
97. Reynolds EH, Carney MW, Toone BK: Methylation and mood. Lancet 1984; 2:196–198Google Scholar
98. Carney MW, Chary TK, Laundy M, Bottiglieri T, Chanarin I, Reynolds EH, Toone B: Red cell folate concentrations in psychiatric patients. J Affect Disord 1990; 19:207–213Google Scholar
99. Bell IR, Edman JS, Morrow FD, Marby DW, Mirages S, Perrone G, Kayne HL, Cole JO: B complex vitamin patterns in geriatric and young adult inpatients with major depression. J Am Geriatr Soc 1991; 39:252–257Google Scholar
100. Nygard O, Refsum H, Ueland PM, Stensvold I, Nordrehaug JE, Kvale G, Vollset SE: Coffee consumption and plasma total homocysteine: the Hordaland Homocysteine Study. Am J Clin Nutr 1997; 65:136–143Google Scholar
101. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM: Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 2003; 60:618–626Google Scholar
102. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM: Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002; 159:2099–2101Google Scholar
103. Penninx BW, Guralnik JM, Ferrucci L, Fried LP, Allen RH, Stabler SP: Vitamin B(12) deficiency and depression in physically disabled older women: epidemiologic evidence from the Women’s Health and Aging Study. Am J Psychiatry 2000; 157:715–721Google Scholar
104. Morris MS, Fava M, Jacques PF, Selhub J, Rosenberg IH: Depression and folate status in the US population. Psychother Psychosom 2003; 72:80–87Google Scholar
